Saturday, February 3, 2018

Roche Drifting Ahead Of Key Data

Things aren't as dire at Roche (OTCQX:RHHBY) as the market may have you believe, but the reality is the company needs to deliver strong clinical data from multiple upcoming late-stage trials. Generics are coming after key drugs that contribute close to 40% of the company's total revenue, and investors need a reason to believe again that Roche can continue to generate worthwhile growth as these veteran contributors start to diminish.

I'm still more or less bullish on the Tecentriq opportunity at Roche, and I believe the company has made more progress with its pipeline than is reflected in the share price. The company definitely needs these upcoming trial read-outs to go well, but I believe the share price undervalues what I believe will be long-term mid-single-digit free cash flow growth.

Read more here:
Roche Drifting Ahead Of Key Data

No comments: